Use of novel compound for treating intractable diseases

The novel compound YJ102 addresses the limitations of current treatments for neuropathic pain, neuroinflammation, and inflammatory skin diseases by inhibiting key inflammatory pathways, providing effective and safer alternatives for managing these conditions.

WO2024242399A1PCT designated stage expired Publication Date: 2024-11-28YJ CERAPEUTICS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006626
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-16
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for neuropathic pain, neuroinflammation, bladder diseases, neurogenic bladder, and inflammatory skin diseases are inadequate, as they often lead to recurrence and are associated with significant side effects, and there is a need for a more effective and safer therapeutic option.

Method used

The use of the novel compound YJ102, which inhibits microglial and astrocyte activation, suppresses inflammatory cytokine expression, and improves bladder function by targeting specific pathways involved in pain and inflammation, thereby providing a comprehensive treatment for neuropathic pain, neuroinflammation, bladder diseases, and inflammatory skin diseases.

Benefits of technology

YJ102 effectively reduces neuropathic pain, improves bladder function, and alleviates symptoms of inflammatory skin diseases, offering superior efficacy compared to conventional drugs with reduced side effects, as demonstrated in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006626_28112024_PF_FP_ABST
    Figure KR2024006626_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: a composition of a novel compound YJ102 for preventing or treating bladder diseases; a composition for preventing or treating neuropathic pain, neuroinflammation or inflammatory skin diseases; or use of the compound for treating intractable nervous system diseases including neurogenic bladder. Compound YJ102 of the present invention inhibits neuropathic pain caused by various causes with an effect superior to those of conventional drugs, alleviates urinary disturbances caused by spinal cord injury, restores bladder hypertrophy and bladder functions, inhibits redness and keratinization, which are major symptoms of psoriasis in a psoriasis animal model, inhibits an increase in epidermal layer thickness, and inhibits spleen hypertrophy caused by psoriasis, and thus can be utilized for treatment of various intractable nervous system diseases or bladder diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Use of novel compounds in the treatment of intractable diseases

[0001] The present invention relates to a composition for preventing or treating neuropathic pain, neuroinflammation, bladder disease or inflammatory skin disease using a novel compound YJ102, or to a use for treating intractable neurological diseases including neurogenic bladder.

[0002] Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described as such damage. It also refers to pain and sensory disturbances caused by stimulation of the cerebral cortex and the limbic system via neural pathways composed of nociceptors and nerve fibers. It can be considered a warning response, signaling abnormalities within or outside the body, acting as a protective mechanism. Pain itself is not a disease, so eliminating it does not cure the underlying disease. Causes can be broadly categorized as perceptual pain, resulting from damage or inflammation of somatic or visceral tissues, or neuropathic pain, resulting from nerve damage. Perceptual pain includes cutaneous pain, visceral pain, somatic pain, perceptual neuralgia, radicular pain, and somatic referred pain. Neuropathic pain is caused by dysfunction of the peripheral or central nervous system. Neuropathic pain is pain resulting from damage or dysfunction of the nervous system, resulting from abnormalities in the transmission or processing of pain signals in the nervous system. Neuropathic pain can be caused by compression, entrapment, or injury to a nerve, infection, diseases such as diabetes or multiple sclerosis, or certain medications. The pain may be described as a burning or stabbing sensation, and may be accompanied by numbness or tingling in the affected area. Neuropathic pain is most often diagnosed based on symptoms, so any pain typically characterized by burning and / or shooting pain and / or numbness and / or tingling and / or allodynia is considered neuropathic. Other features of neuropathic pain include hyperalgesia (significantly excessive painful sensations in response to stimuli), hyperesthesia (increased sensitivity to normal stimuli), dysesthesia (unpleasant, abnormal sensations that occur when no injury has occurred), and tingling (abnormal sensations such as a "pins and needles," either spontaneous or evoked).In the nervous system, glial cells, which are non-neuronal cells, are known to be involved in the development and maintenance of neuropathic pain. In particular, microglia and astrocytes in the spinal cord play a crucial role in the pathogenesis of neuropathic pain. After nerve injury, microglia and astrocytes are activated and secrete pro-inflammatory cytokines and chemokines, which induce an inflammatory response. This exacerbates inflammation and damage to nerve fibers. Furthermore, glial cells contribute to central sensitization, a phenomenon in which neurons in the spinal cord become hypersensitive to pain signals. Therefore, therapies targeting glial cells in the spinal cord are emerging as potential treatments for neuropathic pain. Central hypersensitization refers to the persistent pain caused by changes in the spinal nervous system. Pain stimuli arising in the central nervous system are primarily processed in the spinal dorsal horn.

[0003] Neurons make up the nervous system and are essential for controlling sensory perception, learning, memory, and motor abilities. However, once damaged, they take a long time to recover to normal and, unlike other cells, are difficult to regenerate, increasing the likelihood of permanent damage. In this regard, even within the same nerve cell, damage responses and regenerative abilities differ depending on the location of the injury. Spinal cord injury (SCI), a central nervous system injury, is more likely to result in regeneration failure than other areas. This failure can lead to medical problems such as motor dysfunction and urinary dysfunction, as well as psychological problems. The bladder is a hollow, sac-like muscular organ responsible for storing and excreting urine. Located within the pelvis, behind the pubic symphysis (pubic symphysis), it is connected to the urethra below and the ureters above. In males, the prostate gland is connected below the bladder. The bladder stores approximately 400-500 cc of urine and, in response to neural signals, expels the stored urine through the urethra. Damage to this bladder function can lead to various bladder diseases. The causes of bladder dysfunction can be broadly divided into two categories: functional impairment due to external infections and functional impairment due to physical abnormalities. Among these, functional impairment due to physical abnormalities can be divided into those caused by abnormalities in the bladder itself and those caused by nerve damage. A representative disease caused by bladder dysfunction due to nerve damage is overactive bladder syndrome. This refers to a disease in which the bladder function is overly sensitive due to psychological or pathological factors, causing the bladder muscles to contract abnormally frequently while storing urine, resulting in an urgent urge to urinate and frequent urination.Common symptoms of the above overactive bladder syndrome include frequent urination, urinating more than eight times a day; urinary urgency, which is difficult to hold back the urge to urinate once you feel the need to urinate; nocturia, which is waking up more than twice at night to urinate; and urgency urinary incontinence, which is a sudden, uncontrollable urge to urinate that causes urine leakage. Neurogenic bladder, known as a type of the above overactive bladder syndrome, refers to a disease that exhibits bladder and urethral dysfunction due to damage to the nervous system from various causes, such as diabetes, cerebrovascular accident, brain injury, nerve injury, or spinal cord injury (SCI). Neurogenic bladder can be accompanied by various complications, including urinary tract infections, bladder and kidney damage, and bladder stones. It is known that neurogenic bladder is induced when damage to the nervous system causes an abnormality in the central nervous system related to the urinary tract, as the nerve signals connected to the urinary tract are transmitted abnormally. Since this neurogenic bladder is essentially a derived disease caused by a nerve disease, it is known that overactive bladder syndrome relapses within a short period of time even when treated with known methods, so the development of a treatment method for this has been required.

[0004] Meanwhile, the human immune system protects the body from foreign antigens that invade, but it does not attack its own tissues due to self-tolerance. However, when this self-tolerance is disrupted, immune cells recognize proteins normally expressed by the body's own genes as targets for attack, producing antibodies or triggering T-cell responses to destroy normal tissues. This is called autoimmunity. When specific symptoms appear, it is called an autoimmune disease. The inflammatory response, an immune response, is a repair mechanism that attempts to regenerate damaged areas caused by chemical substances, bacterial infections, and physical actions that cause structural changes in the body or tissues. When inflammation is triggered by harmful stimuli, infections, or trauma, vasoactive substances, such as inflammatory components, are released locally, inducing inflammation. If this inflammatory response persists, it can promote mucosal damage, leading to inflammatory diseases such as rheumatoid arthritis, arteriosclerosis, gastritis, and asthma, which manifest as redness, fever, swelling, pain, and dysfunction. Psoriasis, an inflammatory disease, is a non-contagious, chronic inflammatory skin disease caused by an excessive immune response of abnormally activated T cells. It is an autoimmune disease that requires treatment and is a challenging immune system disorder. In most cases, psoriasis progresses to a long-term condition and can be accompanied by various other diseases, such as psoriatic arthritis, metabolic syndrome, and cardiovascular disease. Approximately 2-3% of the global population suffers from psoriasis. In Korea, the number has increased by approximately 8,500 over the past five years since 2012, reaching a total of 168,000, or approximately 3% of the population. Psoriasis is a skin condition characterized by the formation of erythematous papules and plaques, each with distinct borders and covered with silvery-white scales of varying sizes. Its histological characteristic is epithelial hyperplasia. It also presents with diverse clinical manifestations, including pus, scaling, and rash. The cause of psoriasis remains unknown, but potential contributing factors include genetic factors, environmental triggers or triggers, and immunological factors.Currently, it is known that genetic factors are the cause, along with individual lifestyle and environmental factors, and that immunological factors cause the proliferation of keratinocytes and an inflammatory response. Factors that can worsen or trigger psoriasis include skin trauma, infection, cold and dry climates such as winter, dry skin, stress, and medications. Treatment methods for psoriasis include applying medication to the affected area or phototherapy using ultraviolet rays. Medications used include corticosteroids, vitamin D derivatives, moisturizers, synthetic vitamin A derivatives, immunosuppressants such as cyclosporine, methotrexate, and steroids. However, prolonged application of potent corticosteroids can cause various side effects such as telangiectasia, striae dilatation, and skin atrophy. Cyclosporine can cause kidney damage and blood pressure problems, and cumulative use of methotrexate can cause liver cirrhosis or fibrosis.

[0005] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating neuropathic pain.

[0006] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating neuroinflammation.

[0007] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating bladder diseases.

[0008] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating neurogenic bladder.

[0009] In addition, it is an object of the present invention to provide a composition for improving bladder dysfunction.

[0010] In addition, it is an object of the present invention to provide a composition for suppressing bladder hypertrophy.

[0011] In addition, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating inflammatory skin diseases.

[0012] In addition, an object of the present invention is to provide a cosmetic composition for preventing or improving inflammatory skin diseases.

[0013] In addition, it is an object of the present invention to provide a use for manufacturing a pharmaceutical composition for preventing or treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease.

[0014] In addition, it is an object of the present invention to provide a use for the preparation of a composition for improving bladder dysfunction or suppressing bladder hypertrophy.

[0015] In addition, it is an object of the present invention to provide a method for treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease.

[0016] In addition, it is an object of the present invention to provide a method for treating or improving bladder dysfunction or bladder hypertrophy.

[0017] To achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating neuropathic pain comprising a compound of chemical formula 1.

[0018] In addition, the present invention provides a pharmaceutical composition for preventing or treating neuroinflammation comprising a compound of chemical formula 1.

[0019] In addition, the present invention provides a pharmaceutical composition for preventing or treating bladder disease, comprising a compound of chemical formula 1.

[0020] In addition, the present invention provides a pharmaceutical composition for preventing or treating neurogenic bladder comprising a compound of chemical formula 1.

[0021] In addition, the present invention provides a composition for improving bladder dysfunction comprising a compound of chemical formula 1.

[0022] In addition, the present invention provides a composition for suppressing bladder hypertrophy comprising a compound of chemical formula 1.

[0023] In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammatory skin diseases, comprising a compound of chemical formula 1.

[0024] In addition, the present invention provides a cosmetic composition for preventing or improving inflammatory skin diseases, comprising a compound of chemical formula 1.

[0025] The present invention also provides a use for the preparation of a pharmaceutical composition for the prevention or treatment of neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease using a compound of formula 1.

[0026] In addition, the present invention provides a use for preparing a composition for improving bladder dysfunction or suppressing bladder hypertrophy using a compound of formula 1.

[0027] The present invention also provides a method for treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder, or inflammatory skin disease.

[0028] In addition, the present invention provides a method for treating or improving bladder dysfunction or bladder hypertrophy using a compound of chemical formula 1.

[0029] According to the present invention, the compound YJ102 of the present invention suppresses neuropathic pain caused by various causes with a better effect than conventional drugs, and in particular, it exhibits an effect of suppressing neuroinflammation induced by nerve damage, and improves urination disorders caused by spinal cord injury by suppressing urothelium death, tight junction disruption, cell infiltration, and bladder inflammation, and restores bladder hypertrophy and bladder function, and suppresses flushing and keratinization, which are major symptoms of psoriasis, in a psoriasis animal model, and suppresses an increase in the thickness of the epidermis, and suppresses spleen enlargement caused by psoriasis, and therefore, it has the effect of being utilized for the prevention or treatment of neuropathic pain or neuroinflammation, the prevention or treatment of bladder disease, neurogenic bladder, or bladder dysfunction, and the treatment of inflammatory skin diseases caused by inflammation such as psoriasis.

[0030] Figure 1a is a diagram showing the manufacturing process of a SCI animal model.

[0031] Figure 1b is a diagram showing the manufacturing process of the LSS animal model.

[0032] Figure 1c is a diagram showing the manufacturing process of the SNI animal model.

[0033] Figure 1d is a diagram showing the results of mechanical allodynia measurement in a SCI animal model after oral administration of YJ102.

[0034] Figure 1e is a diagram showing the results of mechanical allodynia measurement in an LSS animal model after oral administration of YJ102.

[0035] Figure 1f is a diagram showing the results of mechanical allodynia measurement in a SNI animal model after oral administration of YJ102.

[0036] Figure 1g is a diagram showing the results of mechanical allodynia measurements in a SCI animal model after intraperitoneal administration of YJ102, gabapentin, or pregabalin.

[0037] Figure 1h shows the results of mechanical allodynia measurements in an LSS animal model after intraperitoneal administration of YJ102, gabapentin, or pregabalin.

[0038] Figure 1i is a diagram showing the results of mechanical allodynia measurements in a SNI animal model after intraperitoneal administration of YJ102, gabapentin, or pregabalin.

[0039] Figure 2a is a diagram showing the immunohistochemical analysis of microglial activation in a SNI animal model:

[0040] Cont: contralateral tissue; and

[0041] Ipsi: Ipsilateral organization.

[0042] Figure 2b is a diagram showing the analysis of microglial activation in the SNI animal model using immunofluorescence chemistry:

[0043] Cont: contralateral tissue; and

[0044] Ipsi: Ipsilateral organization.

[0045] Figure 2c shows Western blot analysis confirming microglial activation in the SNI animal model:

[0046] Cont: contralateral tissue; and

[0047] Ipsi: Ipsilateral organization.

[0048] Figure 3a is a diagram showing immunohistochemical analysis of astroglial activation in a SNI animal model:

[0049] Cont: contralateral tissue; and

[0050] Ipsi: Ipsilateral organization.

[0051] Figure 3b shows Western blot analysis confirming astroglial activation in the SNI animal model:

[0052] Cont: contralateral tissue; and

[0053] Ipsi: Ipsilateral organization.

[0054] Figure 4a is a diagram showing the expression of inflammatory factors in an SNI animal model confirmed by RT-PCR analysis.

[0055] Figure 4b is a diagram showing the expression of inflammatory factors in the SNI animal model confirmed by Western blot analysis.

[0056] Figure 5a is a diagram showing the expression of factors related to the JAK / STAT3 signaling pathway among the inflammation-suppressing mechanisms in the SNI animal model analyzed by Western blot analysis.

[0057] Figure 5b is a diagram showing the expression of factors related to the mTOR signaling pathway among the anti-inflammatory mechanisms in the SNI animal model analyzed by Western blot analysis.

[0058] Figure 5c is a diagram showing the analysis of TRMP7 expression in the SNI animal model by Western blot analysis.

[0059] Figure 5d is a diagram showing the analysis of JMJD3 expression and activation in the SNI animal model by Western blot analysis.

[0060] Figure 6a is a diagram confirming the bladder function improvement effect of YJ102 in a spinal cord injury model through residual urine volume measurement:

[0061] Sham: Group that underwent only laminectomy and no damage;

[0062] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0063] YJ102: YJ102 administration group.

[0064] Figure 6b is a diagram confirming the bladder function improvement effect of YJ102 in a spinal cord injury model using the bladder function score:

[0065] Sham: Group that underwent only laminectomy and no damage;

[0066] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0067] YJ102: YJ102 administration group.

[0068] Figure 6c is a diagram showing the effect of YJ102 on improving bladder function in a spinal cord injury model, as confirmed by the size of the extracted bladder:

[0069] Sham: Group that underwent only laminectomy and no damage;

[0070] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0071] YJ102: YJ102 administration group.

[0072] Figure 6d is a diagram showing the bladder function improvement effect of YJ102 in a spinal cord injury model, as measured by bladder weight:

[0073] Sham: Group that underwent only laminectomy and no damage;

[0074] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0075] YJ102: YJ102 administration group.

[0076] Figure 7a is a diagram showing bladder enlargement confirmed by H&E staining in a spinal cord injury model:

[0077] SCI 1d: 1 day after spinal cord injury;

[0078] Sham: Group that underwent only laminectomy and no damage;

[0079] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0080] YJ102: YJ102 administration group.

[0081] Figure 7b is a diagram confirming the thickness of the urothelium layer, lamina propria, and muscle layer in a spinal cord injury model.

[0082] Figure 7c is a diagram showing the collagen content in the bladder muscle in a spinal cord injury model confirmed by Masson's trichrome staining (Blue: collagen):

[0083] SCI 1d: 1 day after spinal cord injury;

[0084] Sham: Group that underwent only laminectomy and no damage;

[0085] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0086] YJ102: YJ102 administration group.

[0087] Figure 7d is a diagram showing the collagen / muscle ratio (%) within the bladder in a spinal cord injury model:

[0088] SCI 1d: 1 day after spinal cord injury;

[0089] Sham: Group that underwent only laminectomy and no damage;

[0090] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0091] YJ102: YJ102 administration group.

[0092] Figure 8a is a Western blot analysis showing the expression of ZO-1 and Occludin, tight junction proteins of the bladder urothelium, in a spinal cord injury model:

[0093] SCI 1d: 1 day after spinal cord injury;

[0094] Sham: Group that underwent only laminectomy and no damage;

[0095] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0096] YJ102: YJ102 administration group.

[0097] Figure 8b shows the results of immunofluorescence staining of Occludin (Red) within the urothelial layer in a spinal cord injury model:

[0098] Sham: Group that underwent only laminectomy and no damage;

[0099] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0100] YJ102: YJ102 administration group.

[0101] Figure 9a is a diagram showing the influx of MPO (neutrophils) (Green) into the bladder on day 1 after spinal cord injury in a spinal cord injury model using immunofluorescence staining:

[0102] SCI 1d: 1 day after spinal cord injury;

[0103] Sham: Group that underwent only laminectomy and no damage;

[0104] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0105] YJ102: YJ102 administration group.

[0106] Figure 9b is a graph showing the relative fluorescence intensity of MPO-positive cells in the bladder on day 1 after spinal cord injury in a spinal cord injury model:

[0107] Sham: Group that underwent only laminectomy and no damage;

[0108] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0109] YJ102: YJ102 administration group.

[0110] Figure 9c is an immunofluorescence staining showing the influx of ED-1 (macrophage) (Green) into the bladder 7 days after spinal cord injury in a spinal cord injury model:

[0111] SCI 7d: 7 days after spinal cord injury;

[0112] Sham: Group that underwent only laminectomy and no damage;

[0113] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0114] YJ102: YJ102 administration group.

[0115] Figure 9d is a graph showing the relative fluorescence intensity of ED-1 positive cells in the bladder 7 days after spinal cord injury in a spinal cord injury model:

[0116] Sham: Group that underwent only laminectomy and no damage;

[0117] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0118] YJ102: YJ102 administration group.

[0119] Figure 9e shows the results of Western blot analysis of ED-1 in the bladder 7 days after spinal cord injury in a spinal cord injury model:

[0120] Sham: Group that underwent only laminectomy and no damage;

[0121] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0122] YJ102: YJ102 administration group.

[0123] Figure 10a is a diagram showing the results of TUNEL (Blue) staining within the urothelium 3 days after spinal cord injury in a spinal cord injury model:

[0124] Sham: Group that underwent only laminectomy and no damage;

[0125] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0126] YJ102: YJ102 administration group.

[0127] Figure 10b is a graph showing the number of TUNEL-positive cells in the urothelium 3 days after spinal cord injury in a spinal cord injury model:

[0128] Sham: Group that underwent only laminectomy and no damage;

[0129] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0130] YJ102: YJ102 administration group.

[0131] Figure 10c shows the results of Western blot analysis of cleaved caspase-3 (activated caspase-3) in the urothelium 3 days after spinal cord injury in a spinal cord injury model:

[0132] Sham: Group that underwent only laminectomy and no damage;

[0133] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0134] YJ102: YJ102 administration group.

[0135] Figure 10d shows the results of Western blot analysis of UPⅢ (urothelial marker) in the urothelial layer 3 days after spinal cord injury in a spinal cord injury model:

[0136] Sham: Group that underwent only laminectomy and no damage;

[0137] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0138] YJ102: YJ102 administration group.

[0139] Figure 11a is a diagram showing the expression of p75 in the urothelium at 1, 3, and 7 days after spinal cord injury in a spinal cord injury model, analyzed by RT-PCR:

[0140] Sham: Group that underwent only laminectomy and no damage;

[0141] 1d: 1 day after spinal cord injury;

[0142] 3d: 3 days after spinal cord injury; and

[0143] 7d: 7 days after spinal cord injury.

[0144] Figure 11b is a Western blot analysis showing the expression of p75 in the urothelium at 1, 3, and 7 days after spinal cord injury in a spinal cord injury model:

[0145] Sham: Group that underwent only laminectomy and no damage;

[0146] 1d: 1 day after spinal cord injury;

[0147] 3d: 3 days after spinal cord injury; and

[0148] 7d: 7 days after spinal cord injury.

[0149] Figure 11c is a diagram showing the expression of p75 in the urothelium 1 and 7 days after spinal cord injury in a spinal cord injury model using immunofluorescence staining:

[0150] Sham: Group that underwent only laminectomy and no damage;

[0151] 1d: 1 day after spinal cord injury; and

[0152] 7d: 7 days after spinal cord injury.

[0153] Figure 11d shows the results of immunofluorescence staining to identify and count p75 (Red) / TUNEL (Green) dual-expressing cells:

[0154] Sham: Group that underwent only laminectomy and no damage;

[0155] 1d: 1 day after spinal cord injury;

[0156] 7d: 7 days after spinal cord injury;

[0157] U: urothelium;

[0158] L:lamina propria;

[0159] M: muscle layer; and

[0160] Arrow: p75 / TUNEL double-positive cells.

[0161] Figure 11e shows the p75-mediated urothelial apoptosis inhibitory effect of YJ102 in a spinal cord injury model confirmed by RT-PCR analysis of p75:

[0162] 1d: 1 day after spinal cord injury;

[0163] 7d: 7 days after spinal cord injury;

[0164] Sham: Group that underwent only laminectomy and no damage;

[0165] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0166] YJ102: YJ102 administration group.

[0167] Figure 11f shows the p75-mediated urothelial apoptosis inhibitory effect of YJ102 confirmed by Western blot analysis in a spinal cord injury model:

[0168] 1d: 1 day after spinal cord injury;

[0169] 7d: 7 days after spinal cord injury;

[0170] Sham: Group that underwent only laminectomy and no damage;

[0171] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0172] YJ102: YJ102 administration group.

[0173] Figures 12a and c are RT-PCR analysis confirming the expression of NGF in macrophages in a spinal cord injury model:

[0174] Sham: Group that underwent only laminectomy and no damage;

[0175] 1d: 1 day after spinal cord injury;

[0176] 3d: 3 days after spinal cord injury; and

[0177] 7d: 7 days after spinal cord injury.

[0178] Figures 12b and d are Western blot analysis results confirming the expression of NGF and proNGF in macrophages in a spinal cord injury model:

[0179] Sham: Group that underwent only laminectomy and no damage;

[0180] 1d: 1 day after spinal cord injury;

[0181] 3d: 3 days after spinal cord injury; and

[0182] 7d: 7 days after spinal cord injury.

[0183] Figure 12e is a diagram showing double-positive cells for proNGF (Red) and ED-1 (Green) in macrophages in a spinal cord injury model, confirmed by immunofluorescence staining:

[0184] Sham: Group that underwent only laminectomy and no damage; and

[0185] SCI (7 d): 7 days after spinal cord injury.

[0186] Figures 13a and c are RT-PCR results showing the expression of NGF after inflammation induction (LPS treatment) in macrophage cell lines:

[0187] 2 h: 2 hours after LPS treatment;

[0188] 6 h: 6 hours after LPS treatment; and

[0189] 12 h: 12 hours after LPS treatment.

[0190] Figures 13b and d are Western blot analysis results showing the expression of NGF and proNGF after inflammation induction (LPS treatment) in macrophage cell lines:

[0191] 2 h: 2 hours after LPS treatment;

[0192] 6 h: 6 hours after LPS treatment; and

[0193] 12 h: 12 hours after LPS treatment.

[0194] Figure 14a is a diagram showing RT-PCR analysis of inflammatory cytokine and chemokine expression in the bladder in a spinal cord injury model:

[0195] Sham: Group that underwent only laminectomy and no damage;

[0196] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0197] YJ: YJ102 administration group.

[0198] 1d: 1 day after spinal cord injury;

[0199] 3d: 3 days after spinal cord injury; and

[0200] 7d: 7 days after spinal cord injury.

[0201] Figure 14b is a diagram showing the expression of inflammatory factors in the bladder in a spinal cord injury model confirmed by Western blot analysis:

[0202] Sham: Group that underwent only laminectomy and no damage;

[0203] Veh: Control group (group administered with a solution of DMSO, methylpyrrolidinone, and water); and

[0204] YJ: YJ102 administration group.

[0205] 1d: 1 day after spinal cord injury;

[0206] 3d: 3 days after spinal cord injury; and

[0207] 7d: 7 days after spinal cord injury.

[0208] Figure 15a is a diagram showing the analysis of the expression of inflammatory factors by RT-PCR after inflammation was induced in a macrophage cell line (LPS treatment).

[0209] Figure 15b is a graph showing the quantification of the results of 15a.

[0210] Figure 16a is a schematic diagram showing a study on the efficacy evaluation of YJ102 using the IMQ animal model as a psoriasis animal model.

[0211] Figure 16b is a diagram showing the dorsal image of the IMQ animal model mouse on Day 5:

[0212] Sham: Control group with Vaseline cream applied;

[0213] IMQ+Vehicle: Psoriasis animal model group manufactured with IMQ; and

[0214] IMQ+YJ102: Group administered YJ102 to an animal model of psoriasis.

[0215] Figure 16c is a diagram showing the PASI score that evaluates redness in an animal model of psoriasis:

[0216] ham: Control group with Vaseline cream applied;

[0217] IMQ+Vehicle: Psoriasis animal model group manufactured with IMQ; and

[0218] IMQ+YJ102: Group administered YJ102 to an animal model of psoriasis.

[0219] Figure 16d is a diagram showing the PASI score that evaluates the degree of keratinization:

[0220] ham: Control group with Vaseline cream applied;

[0221] IMQ+Vehicle: Psoriasis animal model group manufactured with IMQ; and

[0222] IMQ+YJ102: Group administered YJ102 to an animal model of psoriasis.

[0223] Figure 17a is a diagram showing the results of H&E staining of skin tissue in a psoriasis animal model:

[0224] Sham: Control group with Vaseline cream applied;

[0225] IMQ+Vehicle: Psoriasis animal model group manufactured with IMQ; and

[0226] IMQ+YJ102: Group administered YJ102 to an animal model of psoriasis.

[0227] Figure 17b is a graph showing the quantification of the thickness of the epidermal layer in an animal model of psoriasis:

[0228] Sham: Control group with Vaseline cream applied;

[0229] IMQ+Vehicle: Psoriasis animal model group manufactured with IMQ; and

[0230] IMQ+YJ102: Group administered YJ102 to an animal model of psoriasis.

[0231] Figure 18a is a diagram showing an image of a spleen removed from a psoriasis animal model on Day 6:

[0232] Sham: Control group with Vaseline cream applied;

[0233] Vehicle: Group of psoriasis animal models manufactured with IMQ; and

[0234] YJ102: Group administered YJ102 to psoriasis animal models.

[0235] Figure 18b shows the weight of the spleen extracted from the psoriasis animal model on Day 6:

[0236] Sham: Control group with Vaseline cream applied;

[0237] Vehicle: Group of psoriasis animal models manufactured with IMQ; and

[0238] YJ102: Group administered YJ102 to psoriasis animal models.

[0239] Hereinafter, the present invention will be described in detail with reference to the attached drawings, using exemplary embodiments of the present invention. However, the following exemplary embodiments are provided as examples of the present invention. If a detailed description of a technology or configuration well known to those skilled in the art is judged to unnecessarily obscure the gist of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom.

[0240] In addition, the terminology used in this specification is a term used to appropriately express preferred embodiments of the present invention, and this may vary depending on the intention of the user or operator, or the customs of the field to which the present invention belongs. Therefore, the definition of these terms should be determined based on the contents throughout this specification. Throughout the specification, when a part is said to "include" a certain component, this does not mean that other components are excluded, but rather that other components may be included, unless specifically stated otherwise.

[0241] Unless otherwise defined, all technical terms used in this invention have the same meaning as commonly understood by those skilled in the art. While preferred methods and samples are described herein, similar or equivalent methods are also included within the scope of the present invention. The contents of all publications cited as references herein are incorporated herein by reference.

[0242] Throughout this specification, '%' used to indicate the concentration of a particular substance is (w / w) % for solid / solid, (w / v) % for solid / liquid, and (v / v) % for liquid / liquid, unless otherwise stated.

[0243]

[0244] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating neuropathic pain, comprising a compound of formula 1 (YJ102), an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0245]

[0246] .

[0247] In one embodiment, the neuropathic pain may be neuropathic pain caused by nerve damage, and may be pain due to damage or dysfunction of the peripheral nerves or central nerves.

[0248] In one embodiment, the nerve damage may be multiple sclerosis, Parkinson's disease, stroke, nerve damage due to diabetes, a tumor or malformation of the spinal cord, spinal cord damage caused by trauma or inflammation, or spinal stenosis.

[0249] In one embodiment, the neuropathic pain is diabetic peripheral neuropathic pain, central sensitization, shingles, post-herpetic neuralgia, trigeminal neuralgia, complex regional pain syndrome, reflex sympathetic dystrophy, migraine, phantom limb pain, neuropathic pain due to trauma, neuropathic pain due to nerve injury, neuropathic pain due to spinal stenosis, neuropathic pain due to spinal cord injury, neuropathic pain due to chronic disease (such as multiple sclerosis, HIV), neuropathic pain due to trauma (causalgia), neuropathic pain due to impingement (i.e., sciatica, carpal tunnel, etc.), neuropathic pain due to drug or toxic chemical exposure, neuropathic pain due to infection or post-infection, neuropathic pain due to damaged organ function, neuropathic pain due to vascular disease, neuropathic pain due to metabolic disease, It may be neuropathic pain due to cancer or cancer treatment, neuropathic pain due to an autoimmune disease, neuropathic back pain, neuropathic pain due to fibromyalgia, or idiopathic neuropathic pain.

[0250] In one embodiment, the composition of the present invention can inhibit the activation of microglia or astrocytes.

[0251] In one embodiment, the composition of the present invention can inhibit the expression of JMJD3 (Jumonji domain-containing protein 3), TRPM7 (Transient receptor potential cation channel, subfamily M, member 7), IL-6, iNOS, COX-2, IL-1β, TNF-α, MIP-1α, MIP-1β, MIP-2α, Gro-α, or MCP-1.

[0252] In one embodiment, the composition of the present invention can inhibit phosphorylation of p38MAPK, JAK2, STAT3, S6 or p70S6kinase.

[0253] In one embodiment, the composition of the present invention can increase the level of H3K27Me3 (Trimethylated histone H3 at lysine 27).

[0254] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating neuroinflammation, comprising a compound of formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0255] [Chemical Formula 1]

[0256] .

[0257] In one embodiment, the neuroinflammation may be due to nerve damage, and the nerve damage may be spinal cord injury or spinal stenosis caused by trauma or inflammation.

[0258] In one embodiment, neuroinflammation may be due to activation of microglia or astrocytes.

[0259] In one embodiment, the composition of the present invention can inhibit the expression of JMJD3 (Jumonji domain-containing protein 3), TRPM7 (Transient receptor potential cation channel, subfamily M, member 7), IL-6, iNOS, COX-2, IL-1β, TNF-α, MIP-1α, MIP-1β, MIP-2α, Gro-α, or MCP-1.

[0260] In one embodiment, the composition of the present invention can inhibit phosphorylation of p38MAPK, JAK2, STAT3, S6 or p70S6kinase.

[0261] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating bladder disease, comprising a compound of formula 1 (YJ102), an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0262] [Chemical Formula 1]

[0263] .

[0264] In one embodiment, the bladder disease may be urolithiasis, cystitis, prostate cancer, urinary incontinence, hematuria, bladder cancer, urethritis, prostatitis, urinary frequency, enuresis, urgency, oliguria, acute cystitis, hypospadias, dysuria, bladder stones, urethral stricture, overactive bladder syndrome, chronic cystitis, urinary tract infection, stress urinary incontinence, chronic prostatitis, delayed urination, or chronic bladder failure.

[0265] In one embodiment, the bladder disease may be due to spinal cord injury, wherein the spinal cord injury may be caused by trauma or inflammation.

[0266] In one embodiment, the spinal cord injury may be a traumatic spinal cord injury, a degenerative spinal disease, an inflammatory spinal disease, a spinal tumor, a spinal malformation, a spinal tumor, a spinal cord hemorrhage, a stroke, spinal paralysis due to an extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis, or myelopathy.

[0267] In one embodiment, the composition of the present invention can inhibit bladder hypertrophy.

[0268] In one embodiment, the composition of the present invention can increase the expression of ZO-1 and occludin in the urothelium.

[0269] In one embodiment, the composition of the present invention can protect urothelial cells and inhibit apoptosis of urothelial cells.

[0270] In one embodiment, the composition of the present invention can inhibit the expression of p75, NGF, proNGF, COX-2, iNOS, IL-6, IL-1β, MIP-1α, MIP-1β, MIP-2α or Gro-α.

[0271] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating neurogenic bladder, comprising a compound of formula 1 (YJ102), an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0272] [Chemical Formula 1]

[0273]

[0274] .

[0275] In one embodiment, the neurogenic bladder may be due to spinal cord injury, wherein the spinal cord injury may be caused by trauma or inflammation.

[0276] In one embodiment, the spinal cord injury may be a traumatic spinal cord injury, a degenerative spinal disease, an inflammatory spinal disease, a spinal tumor, a spinal malformation, a spinal tumor, a spinal cord hemorrhage, a stroke, spinal paralysis due to an extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis, or myelopathy.

[0277] In one embodiment, neurogenic bladder may present with symptoms of urinary retention, urgency, urge incontinence, frequency, nocturia, dysuria, dysuria, or pyelonephritis.

[0278] In one embodiment, the composition of the present invention can inhibit bladder hypertrophy.

[0279] In one embodiment, the composition of the present invention can increase the expression of ZO-1 and occludin in the urothelium.

[0280] In one embodiment, the composition of the present invention can protect urothelial cells and inhibit apoptosis of urothelial cells.

[0281] In one embodiment, the composition of the present invention can inhibit the expression of p75, NGF, proNGF, COX-2, iNOS, IL-6, IL-1β, MIP-1α, MIP-1β, MIP-2α or Gro-α.

[0282] In one embodiment, the composition of the present invention comprises a pharmaceutically acceptable salt of the compound of formula 1, and any possible solvate, hydrate, racemate or stereoisomer thereof that can be prepared therefrom.

[0283] In the present invention, the hydrate may contain a stoichiometric or non-stoichiometric amount of water, wherein the compound of formula 1, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and water are non-covalently bound to each other by intermolecular forces. Specifically, the hydrate may contain water in a ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically, may contain about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 2.5 mol, about 3 mol, about 5 mol, etc.

[0284] In the present invention, the solvate is a compound of formula 1, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a solvent other than water, which are bound by intermolecular forces, and may contain the solvent in a stoichiometric or non-stoichiometric amount. Specifically, the solvate may contain solvent molecules in a molar ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically, may contain about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 2.5 mol, about 3 mol, about 5 mol, etc.

[0285] The YJ102 compound represented by the chemical formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and as a salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The acid addition salt is obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkanedioates, aromatic acids, aliphatic and aromatic sulfonic acids. These pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, Contains phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.

[0286] The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the YJ102 compound represented by Chemical Formula 1 in an excess aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Alternatively, the salt can be prepared by evaporating the solvent or excess acid from the mixture to dryness, or by suction filtration of the precipitated salt.

[0287] Additionally, pharmaceutically acceptable metal salts can be prepared using bases. Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. In this case, sodium, potassium, or calcium salts are pharmaceutically suitable as metal salts. Furthermore, the corresponding salts are obtained by reacting an alkali metal or alkaline earth metal salt with a suitable anionic salt (e.g., silver nitrate).

[0288] The pharmaceutical composition of the present invention may additionally contain a known therapeutic agent in addition to the compound of chemical formula 1 as an active ingredient, and may be used in combination with other known treatments for the treatment of the disease.

[0289] In the present invention, the term "prevention" refers to any action that inhibits or delays the occurrence, spread, and recurrence of the disease by administering the pharmaceutical composition according to the present invention, and "treatment" refers to any action that improves or beneficially changes the symptoms of the disease by administering the composition of the present invention. Those of ordinary skill in the art to which the present invention pertains will be able to refer to materials presented by the Korean Medical Association, etc. to know the exact criteria for diseases to which the composition of the present invention is effective, and to determine the degree of improvement, enhancement, and treatment.

[0290] The term "therapeutically effective amount" used in combination with the active ingredient in the present invention means an amount effective in preventing or treating the disease, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the administration method, target site, and patient condition. Therefore, the dosage for use in humans should be determined as an appropriate amount by considering both safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal testing. Such considerations in determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

[0291] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dosage level may be determined based on factors including the patient's health condition, the type and severity of the disease, the activity and sensitivity of the drug, the method of administration, the time of administration, the route and excretion rate, the duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by those skilled in the art.

[0292] The pharmaceutical composition of the present invention may include a carrier, diluent, excipient, or a combination of two or more thereof commonly used in biological preparations. As used herein, the term "pharmaceutically acceptable" means that the composition exhibits a property of not being toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for delivering the composition in vivo, and for example, compounds described in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used. If necessary, other common additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into a main use dosage form such as an aqueous solution, suspension, or emulsion, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or ingredient using an appropriate method in the field or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).

[0293] In one embodiment, the pharmaceutical composition may be in one or more dosage forms selected from the group consisting of oral dosage forms, topical preparations, suppositories, sterile injectable solutions, and sprays.

[0294] In the present invention, the term "administration" means providing a predetermined substance to a subject or patient by any appropriate method, and may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally, or locally in the form of an injection) or orally depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of pain. Liquid preparations for oral administration of the composition of the present invention include suspensions, oral solutions, emulsions, syrups, etc., and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, etc. The pharmaceutical composition of the present invention may be administered by any device that allows the active substance to move to the target site. Preferred administration methods and formulations include intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, and drip injection. Injections can be manufactured using aqueous solvents such as saline solution and Ringer's solution, non-aqueous solvents such as vegetable oil, higher fatty acid ester (e.g., ethyl oleate, etc.), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), and pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).

[0295] In the present invention, the term "subject" means any animal, including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs, that has developed or may develop the disease, and the disease can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to the subject. The pharmaceutical composition of the present invention can be administered in combination with existing therapeutic agents.

[0296] The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive. At this time, the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, maltose, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 to 90 parts by weight, but is not limited thereto.

[0297] In the present invention, the term "expression" generally refers to the cellular process by which a biologically active polypeptide is generated from a DNA sequence and exhibits biological activity in a cell. In this sense, gene expression encompasses not only transcription and translation processes, but also post-transcriptional and post-translational processes that can affect the biological activity of a gene or gene product. These processes include, but are not limited to, RNA synthesis, processing, and transport, as well as polypeptide synthesis, transport, and post-translational modification of the polypeptide.

[0298] In the present invention, the expression can be confirmed by measuring the expression level of a gene or mRNA using a nucleic acid sequence, a nucleic acid sequence complementary to the nucleic acid sequence, a primer pair that specifically recognizes a fragment of the nucleic acid sequence and the complementary sequence, a probe, or a primer pair and a probe, by polymerase chain reaction, real-time RT-PCR, reverse transcription polymerase chain reaction, competitive RT-PCR, nuclease protection assay (RNase, S1 nuclease assay), in situ hybridization, nucleic acid microarray, Northern blot, or DNA chip method, and by using an antibody, antibody fragment, aptamer, avidity multimer, or peptidomimetics that specifically recognizes the full-length protein or a fragment thereof, by Western blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or radioimmunodiffusion method. The expression level of the protein can be measured and confirmed by using radioimmunodiffusion, immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, mass spectrometry, or protein microarray methods.

[0299] In one aspect, the present invention relates to a composition for improving bladder dysfunction comprising a compound of chemical formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0300] [Chemical Formula 1]

[0301] .

[0302] In one embodiment, the bladder dysfunction may be bladder dysfunction due to spinal cord injury, and the spinal cord injury may be traumatic spinal cord injury, spinal degenerative disease, spinal inflammatory disease, spinal tumor, spinal cord malformation, spinal tumor, spinal cord hemorrhage, stroke, spinal paralysis due to extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis, or myelopathy.

[0303] In one embodiment, the composition of the present invention can improve or restore the urinary function of the bladder.

[0304] In one aspect, the present invention relates to a composition for suppressing bladder hypertrophy comprising a compound of chemical formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient:

[0305] [Chemical Formula 1]

[0306] .

[0307] In one embodiment, the composition can inhibit an increase in the thickness of the bladder wall, i.e., the urothelial layer, the lamina propria, or the muscularis propria of the bladder.

[0308] In one aspect, the present invention relates to a food composition for preventing or improving neuropathic pain, comprising a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof:

[0309] [Chemical Formula 1]

[0310] .

[0311] In one aspect, the present invention relates to a food composition for preventing or improving neuroinflammation, comprising a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof:

[0312] [Chemical Formula 1]

[0313] .

[0314] In one aspect, the present invention relates to a food composition for preventing or improving bladder disease, comprising a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof:

[0315] [Chemical Formula 1]

[0316] .

[0317] In one aspect, the present invention relates to a food composition for preventing or improving neurogenic bladder, comprising a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof:

[0318] [Chemical Formula 1]

[0319] .

[0320] In one aspect, the present invention relates to a food composition for improving bladder function or suppressing bladder hypertrophy, comprising a compound of chemical formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof:

[0321] .

[0322] When the composition of the present invention is used as a food composition, the compound of the above chemical formula 1, its isomer, its solvate, its hydrate, or its salt may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The composition may include a food-related acceptable food additive in addition to the active ingredient, and the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment).

[0323] The term "food supplement additive" used in the present invention means a component that can be added to food as an auxiliary, and can be appropriately selected and used by those skilled in the art as added in the manufacture of health functional foods of each formulation. Examples of food supplement additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food supplement additives of the present invention are not limited by the above examples.

[0324] The food composition of the present invention may include a health functional food. The term "health functional food" as used herein refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients having functional properties useful to the human body. Here, "functionality" means obtaining a beneficial effect for health purposes, such as regulating nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be manufactured by a method commonly used in the art, and during the manufacturing process, raw materials and ingredients commonly added in the art can be added. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be manufactured in various forms, and the health functional food of the present invention can be taken as a supplement to enhance the effect of an analgesic.

[0325] In addition, there is no limitation on the type of health food in which the composition of the present invention can be used. In addition, a composition comprising the compound of chemical formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared by mixing other appropriate auxiliary ingredients and known additives that can be included in health functional foods according to the selection of a person skilled in the art. Examples of foods to which the composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and the like can be prepared by adding the compound according to the present invention to juice, tea, jelly, and juice made with the compound as a main ingredient.

[0326] In one aspect, the present invention relates to the use of a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof or a salt thereof, for use in the manufacture of a pharmaceutical composition for the prevention or treatment of neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease.

[0327] In one aspect, the present invention relates to the use of a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof or a salt thereof for use in the manufacture of a composition for improving bladder dysfunction or inhibiting bladder hypertrophy.

[0328] In one aspect, the present invention relates to a method for treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease, comprising administering to a subject suffering from neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof or a salt thereof.

[0329] In one aspect, the present invention relates to a method for treating or improving bladder dysfunction or bladder hypertrophy, comprising administering to a subject having symptoms of bladder dysfunction or bladder hypertrophy a compound of formula 1 of the present invention, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof.

[0330] The present invention is described in more detail through the following examples. However, the following examples are intended only to concretize the content of the present invention and are not intended to limit the present invention.

[0331]

[0332] Example 1. Preparation of nerve injury animal model

[0333] 1-1. Production of animal models of central nervous system damage

[0334] To serve as an animal model of central nervous system injury, a traumatic spinal cord injury (SCI) model was created (Fig. 1a). Specifically, adult male Sprague-Dawley rats weighing 230-250 g were anesthetized with intraperitoneal injection of chloral hydrate (500 mg / kg). The back and neck were shaved, and the spinal cord was exposed without damaging the dura mater. A laminectomy was performed at the T9-T10 level. The spinal processes of T8 and T11 were fixed to stabilize the spine, and a 10-g weight was dropped freely from a height of 25 mm using an NYU impactor onto the dorsal surface of the exposed spinal cord to injure the spine. The muscles and skin were covered, and the rats were placed in a temperature- and humidity-controlled chamber overnight. After surgery, rats were injected subcutaneously with a supplement solution (5 ml, lactated Ringer) and antibiotics (gentamicin, 5 mg / kg, intramuscular injection) once daily for 5 days. Body weight, remaining food, and water weight were recorded for all animals, and the bladders were emptied twice daily through passive bladder massage until reflex micturition was established. At this time, the Sham group was the group that underwent only laminectomy and was not damaged.

[0335]

[0336] 1-2. Production of an animal model of peripheral nerve damage

[0337] 1-2-1. Lumbar spinal stenosis model

[0338] To use it as an animal model of peripheral nerve injury, a lumbar spinal stenosis (LSS) model was created (Fig. 1b). Specifically, adult male Sprague-Dawley rats weighing 260-280 g were anesthetized with intraperitoneal injection of chloral hydrate (500 mg / kg). The back was shaved and the vertebral disc was exposed at the L4 to S2 level. After removing the ligamentous flap between L4 and L5, a trapezoidal silicone block (1.00 mm long x 1.3-1.2 mm wide x 1.0 mm high) was inserted into the epidural space beneath the L5 and L6 vertebral discs without damaging the dural sac. The Sham group was a group in which only a posterior laparotomy was performed without inserting the silicone block.

[0339]

[0340] 1-2-2. Spinal nerve injury (SNI) model

[0341] To utilize it as an animal model of peripheral nerve injury, a spinal nerve injury (SNI) model was created (Fig. 1c). Specifically, adult male Sprague-Dawley rats weighing 200-220 g were anesthetized with intraperitoneal injection of chloral hydrate (500 mg / kg). The three terminal branches of the right sciatic nerve (tibial, common peroneal, and sural nerves) were approached, and the tibia and peroneal nerves were tightly ligated with 4-0 silk. Nerve transection was performed 3 mm distal to the ligation site. The Sham group was a group in which the sciatic nerve was exposed but not injured.

[0342]

[0343] Example 2. Confirmation of the neuropathic pain suppression effect of the compound of the present invention.

[0344] In order to confirm the neuropathic pain suppressing effect of YJ102 (chemical formula 1), a compound of the present invention, in the three nerve injury animal models prepared in Example 1, rats that had been induced to have pain were selected 3 weeks (SNI model) or 4 weeks (SCI model and LSS model) after surgery, and YJ102 dissolved in a solution of DMSO, methyl pyrrolidinone, and water (1:1.5:1) was administered orally (po) at 10 mg / kg or 20 mg / kg, or intraperitoneally (ip) at 1, 2, or 5 mg / kg. For the positive control group, gabapentin or pregabalin dissolved in saline was administered intraperitoneally at a concentration of 5 mg / kg, and for the vehicle group, the same amount of a solution of DMSO, methyl pyrrolidinone, and water was administered. To measure mechanical allodynia, rats were placed on the bottom of a transparent plastic box (10 cm × 10 cm) on a wire mesh (3 mm × 3 mm) and allowed to acclimate for approximately 20 min. Von-Frey filaments were applied to the soles of both paws, using a series of stiff nylon von-Frey monofilaments with logarithmic increases in tactile (mechanical) sensitivity (3.61, 3.84, 4.08, 4.31, 4.56, 4.74, 4.93, and 5.18 mN; Stoelting, WoodDale, IL, USA; equivalent in grams to 0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0, and 15.0). Withdrawal responses of the paws to the increased mechanical stimulus were assessed by applying sufficient force. The von Frey filaments were applied to each paw for 3–4 s to fully flex the paw, and the 50% threshold was determined using the up-down method (Chaplan et al. 1994). The middle 2.0 g (4.A filament of 31 mN was used first, and the most sensitive area was identified in several sites. If no withdrawal response was elicited in the paw, the stimulation was repeated with the next thicker filament. If a withdrawal response was elicited, a weaker filament was applied to the sensitive area. The stimulation was performed at 2-second intervals. The von Frey hair that elicited a 50% withdrawal response to plantar stimulation was expressed as grams (g), and the average value was calculated by measuring both paws. A statistically significant decrease in the withdrawal threshold compared to before spinal cord injury was determined to be the occurrence of mechanical allodynia.

[0345] As a result, when mechanical allodynia was measured using von Frey filaments, the paw withdrawal threshold (PWT) scores in rats 4 weeks after spinal cord injury, 4 weeks after induction of lumbar spinal stenosis, and 3 weeks after nerve injury were significantly lower than those in normal rats (15 points), showing 2-3 points or less (Fig. 1d to f). It was confirmed that all three animal models had lowered pain thresholds, and neuropathic pain was induced even to stimuli that were not painful at all under normal conditions. On the other hand, in all three animal models in which neuropathic pain was induced, when YJ102 was orally administered at 10 mg / kg or 20 mg / kg, the mechanical allodynia threshold increased from 30 minutes after administration, and the analgesic effect lasted for more than 4 hours (Fig. 1d to f). In addition, when YJ102 was administered intraperitoneally to compare its effects with those of gabapentin and pregabalin, which are currently prescribed for neuropathic pain in clinical practice, YJ102 showed an analgesic effect that was more than twice as strong as gabapentin or pregabalin at the same concentration, which showed a significant analgesic effect 1 hour after administration, and the duration of the analgesic effect was also found to be more than three times longer than that of existing drugs (Figs. 1g to 1i). In particular, sedation, a side effect of the drug, was observed when high concentrations of gabapentin (50 mg / kg) and pregabalin (20 mg / kg) were treated, whereas sedation was not observed in the group treated with YJ102 even at a concentration of 100 mg / kg.

[0346] Through this, it was confirmed that the compound YJ102 of the present invention has a remarkable analgesic effect on neuropathic pain compared to drugs (gabapentene, pregabalin) used in conventional clinical practice, and in particular, it was confirmed that there were no side effects observed in conventional drugs even at high concentrations.

[0347]

[0348] Example 3. Analysis of the mechanism of neuropathic pain suppression

[0349] 3-1. Inhibition of microglia and astrocyte activation

[0350] To analyze the activation of microglia in the spinal cord, which are known to play an important role in the induction / persistence of neuropathic pain, the spinal cord of lumbar vertebrae 4-5 was stained with OX-42 4 weeks after nerve injury in a SNI animal model, and changes in cell morphology and intensity were confirmed. Specifically, perfusion was performed through the right atrium of the SNI animal model rat, and the rats were fixed with 4% paraformaldehyde, the spinal nerves (L4-L5) were cut, embedded in OCT compound (optimum cutting temperature compound), and the spinal cord tissue was sectioned at 10 μm thickness using a cryostat. For immunohistochemical staining, anti-OX-42 antibody against OX-42 protein, a marker of microglial cells, was used as the primary antibody on each tissue section and reacted according to the manufacturer's protocol, followed by color development with a secondary antibody (Jackson, USA). In addition, for protein isolation, the sectioned spinal cord tissue was perfused with PBS, sectioned into 1 cm sections centered on the injured area, and homogenized by adding Lysis Buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM MgCl2, 0.1% NP40]. The tissue was transferred to a microcentrifuge tube, rocked at 4°C for 20 minutes, and centrifuged at 25,000 × g for 10 minutes. The supernatant was transferred to a new microcentrifuge, the protein concentration was measured using a BCA kit, and the sample for Western blot was prepared by adding 1X sample buffer and boiling for 5 minutes.For Western blot, equal amounts of protein were loaded onto SDS-PAGE, electrophoresis was performed, and then transferred to a nitrocellulose membrane, which was blotted using primary and secondary antibodies against p38MAPK and p-p38MAPK.

[0351] As a result, microglial cells stained with OX-42 showed a significant increase in OX-42 intensity in the vehicle-administered group compared to the Sham group in both the dorsal horn (contralateral) tissue of the control group on the non-operated side and the ipsilateral tissue of the nerve-injured side, and typical activated microglial cells with thick and short branches were confirmed (Fig. 2a and b). On the other hand, these activation changes were significantly reduced in rats administered YJ102. In addition, the phosphorylation analysis of p38MAPK, which is known to be observed only in activated microglial cells, showed a significant decrease in the amount of p-p38MAPK in rats administered YJ102 (Fig. 2c). Through this, it was confirmed that YJ102 inhibits microglial activation in the spinal cord tissue of a neuropathic pain model.

[0352]

[0353] 3-2. Inhibition of astroglial cell activation

[0354] The activation of astrocytes in the spinal cord, known to play an important role in the process of inducing / persisting neuropathic pain, was confirmed by immunohistochemical staining and Western blot analysis using an anti-GFAP antibody against the intermediate filament protein GFAP (Glial fibrillary acidic protein) of astrocytes, a marker of astrocyte activation, as in Example 3-1.

[0355] As a result, the expression of GFAP was significantly increased in the ipsilateral spinal cord compared to the contralateral spinal cord dorsal horn in the L4-5 spinal cord nerve tissue, and astrocyte activation, which resulted in astrocyte hypertrophy, was observed (Fig. 3a). In contrast, the group administered YJ102 showed a significant decrease in the intensity of GFAP expression, which was also confirmed in the Western blot analysis results (Fig. 3a and b). Through this, it was confirmed that YJ102 inhibits the activation of astrocytes in the spinal cord tissue of a neuropathic pain model.

[0356]

[0357] 3-3. Inhibition of inflammatory factor expression

[0358] It is known that when neuropathic pain occurs, the activation of microglia and astrocytes causes excessive excitation of surrounding nerve cells by expressing inflammatory factors including cytokines and chemokines. Therefore, to confirm the change in the expression of inflammatory factors by YJ102 administration in the SNI animal model 4 weeks after nerve injury, RNA and protein were extracted from L4-5 spinal cord tissue and RT-PCR and Western blot analysis were performed. Specifically, for RT-PCR analysis, RNA was isolated from spinal cord tissue sections using TRIZOL Reagent (Invitrogen) according to the manual, and 1 μg of total RNA was used to make a total mixture (20 μl) and cDNA was synthesized using MMLV reverse transcriptase (Invitrogen). Using the cDNA template and the primers in Table 1 below, the IL-6, iNOS, COX-2, IL-1β, TNF-α, MIP-1α, MIP-1β, MIP-2α, Gro-α, and MCP-1 genes were amplified, respectively, and the results were obtained by electrophoresis on an agarose gel.

[0359]

[0360] As a result, both the RT-PCR results and the Western blot analysis results showed that the inflammatory factors whose expression was significantly increased in the ipsilateral spinal cord tissue after SNI were significantly reduced in the group administered YJ102 (Fig. 4).

[0361]

[0362] 3-4. Signaling Pathway Analysis

[0363] To determine which signaling pathway YJ102 inhibited the neuroinflammatory response, we analyzed the expression changes of factors related to the JAK / STAT3 pathway, mTOR pathway, and TRPM7-mediated pathway, which are known as important regulatory mechanisms and epigenetic regulators mediating the neuroinflammatory response, in the tissues of the SNI animal model 4 weeks after nerve injury, as well as the increased expression and activation of the histone demethylase JMJD3.

[0364] As a result, YJ102 was found to significantly reduce the phosphorylation of JAK2 and STAT3, inhibiting the JAK / STAT3 pathway, and also regulating the mTOR pathway by inhibiting the activity of S6 and p70S6kinase (Fig. 5). In addition, YJ102 was found to inhibit the expression of TRPM7, a non-selective cation ion channel reported to mediate astrocyte activation and cause neuropathic pain (Fig. 5), confirming that YJ102 is associated with the inhibition of astrocyte activation through the inhibition of TRPM7 expression. In addition, YJ102 was found to significantly inhibit the expression of JMJD3, a factor involved in the expression of inflammatory factors such as IL-6 through histone demethylation, and the demethylation activation of H3K27Me3 (Fig. 5), confirming the possibility that this may have an anti-inflammatory effect.

[0365]

[0366] Example 4. Confirmation of the bladder function improvement effect of the compound of the present invention.

[0367] 4-1. Urinary function analysis

[0368] In order to confirm the effect of the compound of the present invention, YJ102 (chemical formula 1), on urinary dysfunction caused by spinal cord injury, immediately after preparing the spinal cord injury (SCI) model prepared in Example 1 (Fig. 1a), YJ102 was dissolved in DMSO, methyl pyrrolidinone, and water (1:1.5:1) and administered intraperitoneally at 5 mg / kg, and then intraperitoneally at 24-hour intervals for 7 days starting the next day. The effect of improving bladder function was analyzed through residual urine volume test and urinary bladder function score (UBFS). At this time, the vehicle group was administered the same amount of a solution of DMSO, methyl pyrrolidinone, and water. Specifically, to determine the amount of urine remaining in the bladder after spinal cord injury, bladder extrusion was performed twice a day by applying pressure to the lower central part of the lower abdomen using the index and middle fingers to empty the bladder, and the expelled urine was collected in a catheter and its volume was recorded. In addition, the bladder function score was assessed daily using a 0-4 point UBFS (0 = total loss of function (manual bladder extrusion 3 times a day, blood in the urine), 1 = partial recovery of UBF (manual extrusion 2 times a day, blood in the urine), 2 = partial recovery of UBF (partial / complete release of sphincter spasm, manual extrusion 1 time a day, persistent blood in the urine), 3 = high recovery (manual extrusion 1 time a day, no blood in the urine), and 4 = normal UBF) as in the reference literature (Zeng et al., Spinal Cord (2017) 55: 834-839).

[0369] As a result, in the case of normal rats (Sham group), the amount of urine in the bladder was almost zero because they could urinate on their own, whereas in the Vehicle group, which could not urinate on their own after spinal cord injury, the amount of residual urine increased significantly compared to the Sham group. However, in the YJ102 administration group, the amount of residual urine decreased significantly compared to the Veh group from the first day of administration (Fig. 6a). In addition, the results of the bladder function recovery analysis using the bladder function score showed that the amount in the YJ102 administration group increased significantly compared to the Vehicle group on the 3rd and 7th days after spinal cord injury (Fig. 6b). In addition, the bladder size and weight were also significantly reduced by YJ102 administration (Figs. 6c and d).

[0370]

[0371] 4-2. Analysis of changes in bladder hypertrophy and collagen content in bladder muscles

[0372] As indicators of bladder dysfunction, we examined bladder hypertrophy, which is a thickening of the bladder wall, and changes in collagen content within the bladder muscle. Specifically, we perfused the animals through the left ventricle of a spinal cord injury model, fixed them with 4% paraformaldehyde, and excised the bladders. Embedded them in optimal cutting temperature compound (OCT), and sectioned the tissues at 10 μm thickness using a cryostat. To measure bladder wall thickness, hematoxylene & eosin (Abcam) staining was performed according to the manufacturer's protocol, and to measure intramuscular collagen content, Masson's trichrome (Sigma-Aldrich) staining was performed.

[0373] As a result, the bladder wall was significantly thickened on the first day after spinal cord injury, and the thickness of the urothelium, lamina propria, and muscle layers that make up the bladder wall were all 2 to 3 times greater than that of the normal group. On the other hand, in the group administered YJ102, the thickness of the urothelium, lamina propria, and muscle layers were all significantly reduced (Figs. 7a and b), and the collagen content in the muscle that was reduced after spinal cord injury was also maintained at a level almost similar to that of the normal group (Figs. 7c and d).

[0374]

[0375] Example 5. Analysis of the treatment mechanism for urinary dysfunction

[0376] 5-1. Inhibition of loss of urothelial tight junction proteins

[0377] When bladder function is abnormal due to spinal cord injury, cystitis, etc., a decrease in tight junction proteins in the urothelium in contact with urine occurs, which increases the permeability of the bladder wall, allowing harmful substances to enter the tissue, causing death of the urothelium that acts as a barrier, and increasing inflammatory responses in the bladder. In order to determine what effect the compound YJ102 of the present invention has on this pathological process, the expression of tight junction proteins ZO-1 and occludin was confirmed by Western blot analysis and immunofluorescence staining, and the influx of neutrophils and macrophages into the bladder was confirmed by immunofluorescence staining. Specifically, the excised bladder tissue sections were frozen in liquid nitrogen, ground in a mortar and pestle to completely disrupt the tissue, and homogenized by adding Lysis Buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM MgCl2, 0.1% NP40]. The samples were transferred to microcentrifuge tubes, rocked at 4°C for 20 min, and centrifuged at 25,000 × g for 10 min. The supernatant was transferred to a new microcentrifuge, and the protein concentration was measured using a BCA kit. 1X sample buffer was added and boiled for 5 min to prepare samples for Western blot. For Western blot, equal amounts of proteins were loaded onto SDS-PAGE, electrophoresis was performed, and then transferred to a nitrocellulose membrane. The membrane was reacted with primary antibodies against Occludin (Invitrogen), ZO-1 (Invitrogen), ED-1 (Serotec), and β-actin (Sigma), and then blotted with secondary antibodies.Additionally, for immunofluorescence staining, 10 μm thick bladder tissue sections were treated with primary antibodies against ZO-1 (Invitrogen), Occludin (Invitrogen), MPO (DAKO), and ED-1 (Serotec), respectively, and reacted according to the manufacturer's protocol, followed by color development with secondary antibodies (Jackson immunoresearh).

[0378] As a result, the amounts of ZO-1 and Occludin were significantly reduced 1 day after spinal cord injury (SCI 1d), and this was significantly suppressed by YJ102 treatment (Fig. 8a). Immunofluorescence staining results also showed that the expression of Occludin in the urothelium was significantly reduced after spinal cord injury, and this Occludin reduction was suppressed by YJ102 treatment (Fig. 8b). In addition, when neutrophils and macrophages in the bladder tissue were examined, it was confirmed that the influx of MPO-positive neutrophils and ED-1-positive macrophages into the bladder after spinal cord injury was significantly suppressed by YJ102 (Fig. 9). This suggests that YJ102 blocks the influx of immune cells into the bladder by protecting tight junction proteins in the urothelium.

[0379]

[0380] 5-2. p75-mediated inhibition of urothelial apoptosis

[0381] The effect of YJ102 on urothelial cell death in bladder tissue after spinal cord injury was confirmed by TUNEL staining. The protein levels of cleaved caspase-3, which indicates caspase-3 activation, and UPⅢ, a urothelial marker, were confirmed by Western blot analysis using primary antibodies p75 (Promega), cleaved caspase-3 (Cell signaling technology), and UPⅢ (Abcam). In addition, to confirm whether the mechanism of cell death was mediated by the p75 neurotrophin receptor, which is involved in urothelial apoptosis, the expression level of p75 was confirmed by RT-PCR, Western blot analysis, and immunofluorescence staining. For RT-PCR analysis, the obtained bladder tissue sections were frozen in liquid nitrogen, ground completely in a mortar and pestle, and RNA was isolated using TRIZOL Reagent (Invitrogen) according to the manual. 1 μg of total RNA was used to prepare a 20 μl total mixture, and cDNA was synthesized using MMLV reverse transcriptase (Invitrogen). The gene expression of p75 was analyzed using the cDNA template and the primers listed in Table 2 below.

[0382]

[0383] TUNEL analysis results showed that the number of TUNEL-positive cells in the urothelium was significantly reduced in the YJ102-administered group compared to the vehicle group (Fig. 10a and b), and caspase-3 activation was also inhibited by YJ102 (Fig. 10c). In addition, the level of UPⅢ, a urothelium marker, was significantly reduced after spinal cord injury (indicating urothelium loss), which was inhibited by YJ102 administration (Fig. 10d). In addition, the gene (mRNA) and protein expression of p75 was significantly increased after spinal cord injury (Fig. 11a to c), and it was confirmed that the urothelium expressing p75 was TUNEL-positive, confirming that p75 mediated the apoptosis process of the urothelium (Fig. 11d). This increased p75 expression was significantly reduced by YJ102 treatment (Fig. 11e and f).

[0384] Through this, we confirmed that YJ102 has a cytoprotective effect that inhibits apoptosis of urothelial cells, and that this is mediated through p75 receptor signaling.

[0385]

[0386] 5-3. Inhibition of proNGF expression

[0387] To determine whether YJ102 affects the production of proNGF, a ligand for p75, the expression of proNGF in the bladder was determined using RT-PCR, Western blot analysis, and immunofluorescence staining. Furthermore, for further validation, Raw 264.7 macrophage cells (Korea Cell Line Bank, Seoul, Korea) were stimulated with 1 μg / ml of LPS, and the effect of YJ102 on proNGF production was investigated. YJ102 was dissolved in DMSO and administered 30 minutes prior to LPS treatment.

[0388] As a result, YJ102 significantly inhibited NGF mRNA expression and proNGF production in bladder tissue after spinal cord injury (Figs. 12a to d), and it was confirmed that proNGF was expressed in macrophages (ED-1 positive cells) that had entered the bladder (Fig. 12e). The results of confirming this in a macrophage cell line also showed that YJ102 significantly inhibited proNGF mRNA and protein expression (Fig. 13).

[0389] This suggests that YJ102 has a cytoprotective effect that suppresses apoptosis of the urothelium by inhibiting the expression of p75 and its ligand, proNGF, in the urothelium of the bladder after spinal cord injury.

[0390]

[0391] 5-4. Inhibition of inflammatory factors

[0392] To confirm the effect of YJ102 on the expression of inflammatory factors in the bladder after spinal cord injury, the expression of inflammatory cytokines and chemokines, COX-2, iNOS, IL-6, IL-1β, MIP-1α, MIP-1β, MIP-2α, and Gro-α in bladder tissues was confirmed by RT-PCR analysis and Western blot analysis using the primers in Table 2 above. In addition, this was also verified by RT-PCR analysis in the Raw 264.7 cell line.

[0393] As a result, it was found that the expression of COX-2, iNOS, IL-6, IL-1β, MIP-1α, MIP-1β, MIP-2α, and Gro-α was all significantly reduced by YJ102 administration (Fig. 14), and it was confirmed that the mRNA levels of IL-1β, TNF-α, IL-6, iNOS, and COX-2, whose expression was increased by LPS treatment in macrophage cell lines, were significantly reduced by YJ102 treatment (Fig. 15).

[0394] Through this, we confirmed that YJ102 can restore bladder function by reducing urothelial cell death, tight junction breakdown, cell infiltration, and resulting inflammatory response in the bladder after traumatic spinal cord injury, and by inhibiting bladder tissue deformation.

[0395]

[0396] Example 6. Preparation of psoriasis animal model

[0397] Psoriasis, which is caused by excessive production of skin cells, is a chronic skin disease associated with various factors including autoimmune diseases, and its symptoms include redness, thickening, and abnormal flaking of the skin. To create an animal model of psoriasis that exhibits important clinical indicators of the disease, such as epidermal thickening, immune cell infiltration in the dermis and epidermis, dyskeratosis, inflammatory response, and activation of the IL-23 / IL-17 cytokine axis, we administered imiquimod (IMQ) to mice. Specifically, the backs of C57BL / 6 mice (male, 18-20 g, 8 weeks) (Daehan Biolink, Eumseong, Republic of Korea) were shaved to remove hair, and IMQ cream (83 mg / day) (5%) was applied to the backs for 5 consecutive days from Day 0 to Day 4 to induce psoriasis-like skin inflammation. Normal control mice (Sham) were treated with petrolatum cream (Fig. 16a).

[0398]

[0399] Example 7. Confirmation of the psoriasis treatment effect of the compound of the present invention.

[0400] 7-1. Relieves redness and flaking

[0401] To confirm the effect of YJ102 (chemical formula 1), a compound of the present invention, on psoriasis, YJ102 dissolved in DMSO, methyl pyrrolidinone, and water (1:1.5:1) was administered intraperitoneally (5 mg / kg) for a total of 3 days on Day 2, Day 3, and Day 4, and the vehicle group was administered the same amount of a solution of DMSO, methyl pyrrolidinone, and water (1:1.5:1) (Fig. 16a). To evaluate daily skin changes, erythema and scaling were evaluated using the PASI score. The PASI score is evaluated on a severity scale of 0-4, where 0 means none, 1 means mild, 2 means moderate, 3 means severe, and 4 means very severe. (PASI Reference: Yashpal Manchanda, Abhishek De, Sudip Das, and Disha Chakraborty. Disease Assessment in Psoriasis. Indian J Dermatol. 2023 May-Jun; 68 (3): 278-281.)

[0402] As a result, the psoriasis mouse model (Vehicle group) manufactured in Example 1 began to show erythema and scaling on the skin from Day 2 after applying IMQ, and the symptoms worsened on Days 4 and 5, with erythema and scaling observed over the entire back. On the other hand, in the group treated with YJ102, the degree of erythema and scaling was significantly lower than in the Vehicle group, and the symptoms appeared to be alleviated on Day 6 (Figs. 16b to d).

[0403]

[0404] 7-2. Inhibition of increase in epidermal thickness

[0405] On Day 6, skin tissues from psoriasis mouse models were stained with Hematoxylin & Eosin, and the epidermal layer thickness was measured. Specifically, on Day 6, the skin of the mouse back was removed, fixed in 4% paraformaldehyde for 24 hours, and paraffin blocks were created, and paraffin tissue sections were prepared at a thickness of 5 μm. To measure the thickness of the epidermal layer, paraffin tissues were stained with Hematoxylene & Eosin (Abcam) according to the manufacturer's protocol, and photographs were taken of five epidermal layers from each mouse at 200x magnification using an optical microscope. The epidermal layer thickness was measured in the tissues of a total of five mice (a total of 25 sections), and the average value was calculated.

[0406] As a result, the Sham group, which is a normal control group, had an epidermal layer thickness of 36.6 ± 2.3 μm, and the Vehicle group, which is a psoriasis-inducing group, had an epidermal layer thickness of 141.3 ± 7.5 μm, which was approximately 38 times thicker than the Sham group. On the other hand, the epidermal layer thickness of the group administered YJ102 was 89.8 ± 6.8 μm, which was approximately 35% thicker than that of the Vehicle group. In addition, it was observed that a significant number of cells had entered the dermal layer in the skin tissue of the Vehicle group, but in the YJ102 administered group, the number was found to have decreased to the Sham level (Fig. 17).

[0407] Through this, it was confirmed that YJ102 can alleviate the symptoms of psoriasis.

[0408]

[0409] Example 8. Confirmation of the inhibitory effect of the compound of the present invention on splenomegaly caused by psoriasis.

[0410] Splenomegaly occurred in mice induced with psoriasis, and the longitudinal diameter of the spleen in psoriasis patients was reported to be increased compared to non-psoriasis patients, and a correlation between the disease duration and spleen diameter was reported. Therefore, on Day 6, the spleens of each group were removed and weighed to determine the degree of splenomegaly.

[0411] As a result, the size and weight of the spleen in the YJ102 group were significantly reduced compared to the vehicle group (Fig. 18). Therefore, the result that YJ102 reduces splenomegaly in the IMQ psoriasis animal model suggests that YJ102 has the potential to modulate immune system abnormalities in psoriasis patients.

Claims

1. A pharmaceutical composition for preventing or treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder, or inflammatory skin disease, comprising a compound of chemical formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient: [Chemical Formula 1] .

2. A pharmaceutical composition according to claim 1, wherein neuropathic pain includes pain caused by damage or dysfunction of peripheral nerves or central nerves.

3. In paragraph 1, the neuropathic pain is diabetic peripheral neuropathic pain, central sensitization, shingles, post-herpetic neuralgia, trigeminal neuralgia, complex regional pain syndrome, reflex sympathetic dystrophy, migraine, phantom limb pain, neuropathic pain due to trauma, neuropathic pain due to nerve injury, neuropathic pain due to spinal stenosis, neuropathic pain due to spinal cord injury, neuropathic pain due to chronic disease (multiple sclerosis, HIV, etc.), neuropathic pain due to trauma (causalgia), neuropathic pain due to collision (i.e., sciatica, carpal tunnel, etc.), neuropathic pain due to drug exposure or toxic chemical exposure, neuropathic pain due to infection or after infection, neuropathic pain due to damaged organ function, neuropathic pain due to vascular disease, neuropathic pain due to metabolic disease A pharmaceutical composition for use in treating neuropathic pain, neuropathic pain due to cancer or cancer treatment, neuropathic pain due to an autoimmune disease, neuropathic back pain, neuropathic pain due to fibromyalgia, or idiopathic neuropathic pain.

4. A pharmaceutical composition according to claim 1, which inhibits the activation of microglia or astrocytes.

5. A pharmaceutical composition according to claim 1, which inhibits the expression of p75, NGF, proNGF, IL-6, JMJD3 (Jumonji domain-containing protein 3), TRPM7 (Transient receptor potential cation channel, subfamily M, member 7), IL-6, iNOS, COX-2, IL-1β, TNF-α, MIP-1α, MIP-1β, MIP-2α, Gro-α or MCP-1.

6. A pharmaceutical composition according to claim 1, which inhibits phosphorylation of p38MAPK, JAK2, STAT3, S6 or p70S6kinase.

7. A pharmaceutical composition according to claim 1, which increases H3K27Me3 (Trimethylated histone H3 at lysine 27).

8. A pharmaceutical composition according to claim 1, wherein the neuroinflammation includes neuroinflammation caused by activation of microglia or astrocytes.

9. In paragraph 1, the bladder disease is urinary stones, cystitis, prostate cancer, urinary incontinence, hematuria, bladder cancer, urethritis, prostatitis, frequent urination, enuresis, urgency, oliguria, acute cystitis, hypospadias, dysuria, bladder stones, urethral stricture, overactive bladder syndrome, chronic cystitis, urinary tract infection, stress urinary incontinence, chronic prostatitis, delayed urination, or chronic bladder insufficiency, a pharmaceutical composition.

10. A pharmaceutical composition according to claim 9, wherein the bladder disease is caused by spinal cord damage.

11. A pharmaceutical composition according to claim 10, wherein the spinal cord injury is traumatic spinal cord injury, spinal degenerative disease, spinal inflammatory disease, spinal tumor, spinal cord malformation, spinal tumor, spinal cord hemorrhage, stroke, spinal paralysis due to extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis, or spinal stenosis.

12. A pharmaceutical composition according to claim 1, wherein the neurogenic bladder is caused by spinal cord injury.

13. A pharmaceutical composition according to claim 12, wherein the spinal cord injury is traumatic spinal cord injury, spinal degenerative disease, spinal inflammatory disease, spinal tumor, spinal cord malformation, spinal tumor, spinal cord hemorrhage, stroke, spinal paralysis due to extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis, or spinal stenosis.

14. A pharmaceutical composition according to claim 1, wherein the neurogenic bladder exhibits symptoms of urinary retention, urgency, urgency incontinence, frequent urination, nocturia, dysuria, urination disorder or pyelonephritis.

15. A pharmaceutical composition for treating or alleviating splenomegaly or bladder enlargement according to claim 1.

16. A pharmaceutical composition according to claim 1, which increases the expression of ZO-1 and occludin in urothelium.

17. A pharmaceutical composition according to claim 1, which protects urothelial cells.

18. A pharmaceutical composition according to claim 1, wherein the inflammatory skin disease is an autoimmune skin disease, a proliferative skin disease, a fibrous skin disease, contact dermatitis, seborrheic dermatitis, scleroderma, skin immune hypersensitivity, atopic dermatitis, urticaria, pruritus, psoriasis or eczema.

19. A pharmaceutical composition according to claim 18, wherein the psoriasis is guttate psoriasis, plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, and exfoliative psoriasis.

20. A pharmaceutical composition according to claim 1, which suppresses or alleviates erythema, scaling, or increased thickness of epidermal tissue.

21. Composition for improving bladder dysfunction comprising a compound of chemical formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient: [Chemical Formula 1] .

22. In claim 21, bladder dysfunction is bladder dysfunction caused by spinal cord injury, composition for improving bladder dysfunction.

23. A composition for improving bladder dysfunction in claim 22, wherein the spinal cord injury is traumatic spinal cord injury, spinal degenerative disease, spinal inflammatory disease, spinal tumor, spinal cord deformity, spinal tumor, spinal cord hemorrhage, stroke, spinal paralysis due to extramedullary vascular disorder, myelitis, multiple sclerosis, amyotrophic lateral sclerosis or spinal stenosis.

24. A composition for improving bladder dysfunction, which improves or restores the urinary function of the bladder in claim 21.

25. Composition for suppressing bladder hypertrophy comprising a compound of chemical formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient: [Chemical Formula 1] .

26. A composition for suppressing bladder hypertrophy, which suppresses an increase in the thickness of the urothelial layer, the lamina propria, or the muscular layer of the bladder in claim 25.

27. A cosmetic composition for preventing or improving inflammatory skin disease, comprising a compound of chemical formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof as an active ingredient: [Chemical Formula 1] .

28. A cosmetic composition for preventing or improving inflammatory skin diseases, wherein the cosmetic composition is prepared in one or more formulations selected from the group consisting of skin, lotion, cream, essence, emulsion, gel, hand cream, lipstick, cleansing foam, cleansing cream, cleansing water, spray, shampoo, rinse, treatment, body cleanser, soap, pack, massage agent, face powder, compact, foundation, two-way cake, and makeup base.

29. Use of a compound of formula 1, an isomer thereof, a solvate thereof, a hydrate thereof or a salt thereof for use in the manufacture of a pharmaceutical composition for the prevention or treatment of neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder or inflammatory skin disease: [Chemical Formula 1] .

30. Use of a compound of formula 1, an isomer thereof, a solvate thereof, a hydrate thereof or a salt thereof for use in the manufacture of a composition for improving bladder dysfunction or suppressing bladder hypertrophy: [Chemical Formula 1] .

31. A method for treating neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder, or inflammatory skin disease, comprising administering to a subject suffering from neuropathic pain, neuroinflammation, bladder disease, neurogenic bladder, or inflammatory skin disease a compound of formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof: [Chemical Formula 1] .

32. A method for treating or improving bladder dysfunction or bladder hypertrophy, comprising administering a compound of formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a salt thereof to a subject having bladder dysfunction or bladder hypertrophy: [Chemical Formula 1] .

Citation Information

Patent Citations

  • Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives

    KR1020080043380A

  • Ae source locating system and method thereof

    KR1020200119565A

  • Non-aqueous electrolyte and lithium secondary battery comprising the same

    KR1020240127845A

  • System and method for automatically detecting structural damage by generating super resolution digital images

    KR102157610B1

  • Composition for treating spinal cord injury, comprising stem cells treated with novel compound

    WO2021100889A1